Figure 7.
Strategies to select against MAPKi-resistant melanoma. Schematic showing MAPKi-addiction phenotypes being driven by p-ERK rebound levels and potential therapeutic strategies (enhancing p-ERK or impairing DNA damage repair) that promote tumor cell-death (apoptosis or parthanatos) or regression.